The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Immune checkpoint inhibitors have revolutionized cancer treatment, yet many tumours develop strategies to evade or suppress immune responses, limiting long-term efficacy. This webcast will examine how ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...

The fight against cancer is undergoing a paradigm shift with the emergence of innovative strategies in Cancer Immunity & Immunotherapy. These approaches harness the body's own immune system to ...

Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...